Condition: Metastatic Pancreatic Cancer · Advanced Pancreatic Cancer · Sponsor: Centre Leon Berard
The proposal is to implement a molecular screening program for advanced/metastatic pancreatic cancer patients before the initiation of 1st line treatment in order to allow a better selection of patients for rationale personalized medicine with targeted agents and/or combination involving a chemotherapy backbone.
This description comes directly from the study's public registry record.
Philippe CASSIER, MD, PhD · 0426556833 · philippe.cassier@lyon.unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre Léon Bérard | Lyon, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05380414